RT Journal Article
T1 Towards the sustainable discovery and development of new antibiotics.
A1 Miethke, Marcus
A1 Pieroni, Marco
A1 Weber, Tilmann
A1 Brönstrup, Mark
A1 Hammann, Peter
A1 Halby, Ludovic
A1 Arimondo, Paola B
A1 Glaser, Philippe
A1 Aigle, Bertrand
A1 Bode, Helge B
A1 Moreira, Rui
A1 Li, Yanyan
A1 Luzhetskyy, Andriy
A1 Medema, Marnix H
A1 Pernodet, Jean-Luc
A1 Stadler, Marc
A1 Tormo, José Rubén
A1 Genilloud, Olga
A1 Truman, Andrew W
A1 Weissman, Kira J
A1 Takano, Eriko
A1 Sabatini, Stefano
A1 Stegmann, Evi
A1 Brötz-Oesterhelt, Heike
A1 Wohlleben, Wolfgang
A1 Seemann, Myriam
A1 Empting, Martin
A1 Hirsch, Anna K H
A1 Loretz, Brigitta
A1 Lehr, Claus-Michael
A1 Titz, Alexander
A1 Herrmann, Jennifer
A1 Jaeger, Timo
A1 Alt, Silke
A1 Hesterkamp, Thomas
A1 Winterhalter, Mathias
A1 Schiefer, Andrea
A1 Pfarr, Kenneth
A1 Hoerauf, Achim
A1 Graz, Heather
A1 Graz, Michael
A1 Lindvall, Mika
A1 Ramurthy, Savithri
A1 Karlén, Anders
A1 van Dongen, Maarten
A1 Petkovic, Hrvoje
A1 Keller, Andreas
A1 Peyrane, Frédéric
A1 Donadio, Stefano
A1 Fraisse, Laurent
A1 Piddock, Laura J V
A1 Gilbert, Ian H
A1 Moser, Heinz E
A1 Müller, Rolf
K1 Business strategy in drug development
K1 Drug therapy
AB An ever-increasing demand for novel antimicrobials to treat life-threatening infections caused by the global spread of multidrug-resistant bacterial pathogens stands in stark contrast to the current level of investment in their development, particularly in the fields of natural-product-derived and synthetic small molecules. New agents displaying innovative chemistry and modes of action are desperately needed worldwide to tackle the public health menace posed by antimicrobial resistance. Here, our consortium presents a strategic blueprint to substantially improve our ability to discover and develop new antibiotics. We propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding, aiming to bridge the gap between academic, industrial and political stakeholders, and to unite interdisciplinary expertise in order to efficiently fuel the translational pipeline for the benefit of future generations.
SN 2397-3358
YR 2021
FD 2021-08-19
LK http://hdl.handle.net/10668/18403
UL http://hdl.handle.net/10668/18403
LA en
DS RISalud
RD Apr 7, 2025